Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: Implications for future trials

Human Vaccines

Volumn 2, Issue 3, 2006, Pages 134-136

  De Rose, Robert ^a   Sullivan, Mark T ^a,b   Dale, C Jane ^a   Kelleher, Anthony D ^b   Emery, Sean ^b   Cooper, David A ^b   Ramshaw, Ian A ^c   Boyle, David B ^d   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Biology and Environment   (Australia)

^d CSIRO   (Australia)

Author keywords

Body surface area; Immunologic dose response relationship; Prime boost; Vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FOWLPOX VIRUS; HUMAN; IMMUNOGENICITY; MACACA; MONKEY; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33748092412     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2940     Document Type: Article

References (29)

1. Nathanson N, Mathieson BJ. Towards an AIDS vaccine: The role of nonhuman primates. J Med Primatol 1999; 28:146-53.
2. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
3. Dale CJ, De Rose R, Stratov I, et al. Efficacy of DNA and Fowlpox virus prime/boost vaccines for Simian/Human Immunodeficiency Virus. J Virol 2004; 78:13819-28.
4. Cohen J. AIDS vaccines: HIV dodges one-two punch. Science 2004; 305:1545-7.
5. Guimaraes-Walker A, Mackie N, McMichael A, et al. Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection [abstract 55]. Lausanne Switzerland: Paper presented at: Program and Abstracts of AIDS Vaccine 04.
6. Hanke T, Samuel RV, Blanchard TJ, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-32.
7. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343-52.
8. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911-9.
9. De Rose R, Chea S, Dale CJ, et al. Subtype AE HIV-1 DNA and recombinant Fowlpox virus vaccines encoding five shared HIV-1 genes: Safety and T cell immunogenicity in macaques. Vaccine 2005; 23:1949-56.
10. Dale CJ, De Rose R, Wilson K, et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and Fowlpox virus vaccines coexpressing IFNg or IL-12. Vaccine 2004; 23:188-97.
11. Pamungkas J, De Rose R, Iskandriati D, et al. Comparison of whole gene and whole virus scrambled antigen approaches for DNa and FPV boost HIV-1 vaccine regimens in macaques. AIDS Res Hum Retroviruses 2005; In press.
12. Kelleher AD, Puls RL, Bebbington M, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Aids 2006; 20:294-7.
13. Mosteller RD. Simplified calculation of body surface area. NEJM 1987; 317:1098.
14. Deralenko MJ. Toxicologists Pocket Handbook. CRC Press, 2000.
15. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001; 19:171-7.
16. McConkey SJ, Recce WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant vaccina virus Ankara in humans. Nat Med 2003; 9:729-35.
17. Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164:4968-78.
18. Wee EG, Patel S, McMichael AJ, Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 2002; 83:75-80.
19. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
20. Graham BS, Tavel J, Koup R, et al. Phase I clinical studies of DNA vaccines for HIV, AIDS Vaccine 2003. New York: 2003.
21. Ruxrungtham K, Kroon ED, Ungsedhapand C, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. Aids 2000; 14:1375-82.
22. Johnson PR, Schnepp BC, Connell MJ, et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79:955-65.
23. Fast P. Development of AAV HIV Vaccines. 2005; (Montreal), Paper presented at: AIDS Vaccine 2005.
24. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
25. Isaacs R, Evaluating the efficacy of the Merck Ad5 based trivalent HIV vaccine. Paper presented at: AIDS Vaccine 2005. 2005, (Montreal).
26. Goepfert PA, Horton H, McElrath MJ, et al. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192:1249-59.
27. Stannard LM, Marais D, Kow D, Dumbell KR. Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin. J Gen Virol 1998; 79:1637-46.
28. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993; 197:439-44.
29. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.